The Summary
In a phase 2a randomized clinical trial, researchers evaluated the effects of weekly semaglutide versus placebo over nine weeks in 24 adults who smoke daily. While semaglutide did not significantly increase laboratory-measured smoking resistance or reduce the self-reported weekly cigarettes per day compared to the placebo, it did yield encouraging secondary outcomes. Participants receiving semaglutide experienced significantly reduced nicotine cravings, lower body weight, and some relief from withdrawal symptoms. Laboratory-measured smoking self-administration also decreased in supplementary analyses, suggesting potential efficacy for smoking cessation.
Why this is interesting
For years, GLP-1 receptor agonists like semaglutide have been praised for weight management and diabetes control. This study suggests their benefits might extend to combating addiction by targeting the brain's reward pathways. While it did not outright stop participants from smoking, the significant reduction in nicotine cravings and withdrawal symptoms is a major breakthrough. For readers, this opens the door to future, larger clinical trials that could establish semaglutide as a multi-purpose tool to help people quit smoking while simultaneously managing post-cessation weight gain and protecting cardiovascular health.